Now recruiting patients with ulcers for a study supported by NHS England

Contact us if your ulcer is less than 6 weeks old and you live in South-East England

Goal is to determine patient and economic benefits of using Acapsil as first-line treatment at GP-surgeries. Acapsil is already approved and available for sale over-the-counter.

To participate, your venous leg ulcers or diabetic foot ulcers must be less than 6 weeks old.
You must live in Hampshire, East Dorset, West Surrey, Berkshire or the western part of West Sussex.

Goal is to determine patient and economic benefits of using Acapsil as first-line treatment at GP-surgeries. Acapsil is already approved and available for sale over-the-counter.

To participate, your venous leg ulcers or diabetic foot ulcers must be less than 6 weeks old.
You must live in Hampshire, East Dorset, West Surrey, Berkshire or the western part of West Sussex.

60% quicker
than antibiotics

at removing infection

at removing infection

at removing infection

Passive Immunotherapy

Acting via the skin microbiome

Acting via the skin microbiome

Acting via the skin microbiome

Removes pain,
smell and discharge

by efficiently removing the infection

by efficiently removing the infection

by efficiently removing the infection

Less Scarring

"Where I have used Acapsil the scarring is flat, whereas the older scars are hypertrophic." ST

"Where I have used Acapsil the scarring is flat against the surrounding skin, whereas the older scars are bulging / hypertrophic." ST

"Where I have used Acapsil the scarring is flat against the surrounding skin, whereas the older scars are bulging / hypertrophic." ST

"Acapsil changed my life."

"From 4 weeks of absolute hell - to being pain-free, getting a full night's sleep and back to normal at work."

"From 4 weeks of absolute hell, in pain 24 hours a day, struggling at work - to being pain-free, getting a full night's sleep and back to normal at work."

"From 4 weeks of absolute hell, in pain 24 hours a day, struggling at work - to being pain-free, getting a full night's sleep and back to normal at work."

NH ( patient)

NH ( patient)

NH ( patient)

Did you know:
killing the microbes in your wound makes YOU resistant!

MPPT removes infection without killing

MPPT removes infection without killing

MPPT removes infection without killing

69.5% Savings

Cost-effectiveness determined in NHS Clinical Audit

Cost-effectiveness determined in NHS Clinical Audit

Cost-effectiveness determined in NHS Clinical Audit

Hypoallergenic

Only natural ingredients

Only natural ingredients

Only natural ingredients

FDA Executive Review:

Antibiotic and antiseptic dressings do not improve wound infections or wound healing.

Antibiotic and antiseptic dressings do not improve wound infections or wound healing.

Antibiotic and antiseptic dressings do not improve wound infections or wound healing.

US FDA 2016

US FDA 2016

US FDA 2016

In connection with publication on MPPT, the

In connection with publication on MPPT, the

In connection with publication on MPPT, the

Chair of WHO Anti-Microbial-Resistance group said:

“AMR is an escalating global threat. We need alternative treatments, including innovative ways to use the body’s own immune system and healthy bacteria.”

“AMR is an escalating global threat. We need alternative treatments, including innovative ways to use the body’s own immune system and healthy bacteria.”

“AMR is an escalating global threat. We need alternative treatments, including innovative ways to use the body’s own immune system and healthy bacteria.”

“For me, this Acapsil open air method is a no brainer. It is easier, no fuss, and obviously cheaper than these expensive dressings.”

VH (patient)

VH (patient)

VH (patient)

previous arrow
next arrow
Slider
Willingsford is a British healthcare company. It was founded in 2010 for the purpose of pursuing MPPT in wound healing. At the time, studies had demonstrated that the technology was effective in wound healing, but for commercialisation, the technology still had a long way to go. The mode-of-action was not completely understood, it was necessary to develop the manufacturing process and to achieve regulatory approval. Willingsford was therefore established and with the help of a UK government grant, the goal of gaining the CE-mark was achieved in July 2016. Following approval, products based on MPPT were launched in the UK and the rest of Europe. In March 2017, Willingsford received a second UK government grant to support the further development of MPPT. Since launch, MPPT has been used by several hospitals and in community care and it has been able to promote the healing of a number of "non-healing" wounds. Many have described MPPT as a disruptive technology because it is based on completely new principles and because it can help wounds that no longer could be helped by existing approaches. However, its novelty also means that its acceptance takes time. It has been estimated that it takes around 9-10 years for a new technology to be fully accepted by the medical profession. MPPT is available for human and veterinary wound healing in the EU and efforts to seek regulatory approval in other territories are ongoing. In parallel with these activities, Willingsford is actively pursuing a number of other healthcare technologies. Willingsford is looking for partners and distributors around its wound healing technology.
Close Menu
Close Panel